EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
Zhen Qin(Chinese Academy of Sciences), Hongbin Ji(Westlake University), Hiroki Izumi(National Cancer Center Hospital East), Zhaoyuan Fang(Second Affiliated Hospital of Zhejiang University), Meiting Yue(Chinese Academy of Sciences), Fengying Wu(Shanghai Sixth People's Hospital), Luonan Chen(Shanghai Jiao Tong University), Shengxiang Ren(Tongji University), Kwok‐Kin Wong(NYU Langone Health), Xinyuan Tong(Chinese Academy of Sciences), Andrea Ventura(Memorial Sloan Kettering Cancer Center), Fei Li(Shanghai Medical College of Fudan University), Kōichi Goto(National Cancer Center Hospital East), Honghua Sun(Chinese Academy of Sciences), Shijie Tang(Chinese Academy of Sciences), Xiumin Yan(XinHua Hospital), Susumu Kobayashi(Beth Israel Deaconess Medical Center), Tetsuro Taki(National Cancer Center Hospital East), Yun Xue(Chinese Academy of Sciences), Yisheng Fang(Nanfang Hospital), Yijun Gao(Sun Yat-sen University), Hsin‐Yi Huang(Center for Excellence in Molecular Cell Science), Yujuan Jin(Chinese Academy of Sciences), Xueliang Zhu(Shanghai Institutes for Biological Sciences), Liang Chen(Henan Medical University), Yuan Li(Sichuan University), Liang Hu(Ministry of Agriculture and Rural Affairs), Haiquan Chen(Fudan University Shanghai Cancer Center), Yongchang Zhang(Central South University), Fuming Li(Fudan University), Wanying Wang(Tongji University), Shunta Mori(National Cancer Center Hospital East), Guoliang Xu(Chinese Academy of Sciences)
Cited by 21
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Restoration of p53 function leads to tumour regression in vivo
|Nature|2007|1.8k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k